2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Retrograde synaptic inhibition is mediated by α-Neurexin binding to the α2δ subunits of N-type calcium channels

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          The synaptic adhesion molecules Neurexin and Neuroligin alter the development and function of synapses and are linked to autism in humans. In C. elegans, post-synaptic Neurexin (NRX-1) and pre-synaptic Neuroligin (NLG-1) mediate a retrograde synaptic signal that inhibits acetylcholine (ACh) release at neuromuscular junctions. Here we show that the retrograde signal decreases ACh release by inhibiting the function of pre-synaptic UNC-2/CaV2 calcium channels. Post-synaptic NRX-1 binds to an auxiliary subunit of pre-synaptic UNC-2/CaV2 channels (UNC-36/α2δ) decreasing UNC-36 abundance at pre-synaptic elements. Retrograde inhibition is mediated by a soluble form of NRX-1’s ectodomain, which is released from the post-synaptic membrane by the SUP-17/ADAM10 protease. Mammalian Neurexin-1α binds α2δ–3 and decreases CaV2.2 current in transfected cells whereas Neurexin-1α has no effect on CaV2.2 reconstituted with α2δ1 and α2δ2. Collectively, these results suggest that α-Neurexin binding to α2δ is a conserved mechanism for regulating synaptic transmission.

          Related collections

          Author and article information

          Journal
          8809320
          1600
          Neuron
          Neuron
          Neuron
          0896-6273
          1097-4199
          17 June 2017
          29 June 2017
          19 July 2017
          19 July 2018
          : 95
          : 2
          : 326-340.e5
          Affiliations
          [1 ]Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA
          [2 ]Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA
          [3 ]Program in Neuroscience, Harvard Medical School
          [4 ]Department of Neuroscience and Brown Institute for Brain Science, Brown University, Providence, RI 02912
          [5 ]Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Australia
          Author notes
          [* ]Lead contact. Correspondence to: kaplan@ 123456molbio.mgh.harvard.edu
          Article
          PMC5548138 PMC5548138 5548138 nihpa885313
          10.1016/j.neuron.2017.06.018
          5548138
          28669545
          4c2e239d-6341-4aa4-bb82-7428534e3e18
          History
          Categories
          Article

          Comments

          Comment on this article